✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
18 Years+
About This Trial
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Who Can Join?
Inclusion Criteria: * Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations * Age โฅ18 years or legal age of majority if >18 years in the participant's country of residence * Current hospitalization or recently discharged with the primary diagnosis of heart failure * Heart failure signs and symptoms at the time of hospital admission * Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) โฅ500 pg/mL or B-type natriuretic peptide (BNP) โฅ125 pg/mL according to the local lab for patients in sinus rhythm; or elevated NTproBNP โฅ1500 pg/mL or BNP โฅ375 pg/mL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission * Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization) * Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide,…
⚠ Always speak to your doctor before applying to any clinical trial.
More Heart & Circulation Trials
Recruiting PHASE3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired…
RecruitingMechanisms of Atrial Pathoelectrophysiology in HCM
RecruitingNovel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure…